His main research interests are gastrointestinal oncology, early phase clinical trials and translational research. He pioneered Hong Kong Liver Cancer classification, which has revolutionized the treatment algorithm of liver cancer patients. Moreover, he has actively involved in cancer drug development, especially in the field of caner immunotherapy. He has led few global ground-breaking immunotherapy trials for liver cancer and some of these trials led to global drug approval for advanced hepatocellular carcinoma patients. He has published more than 200 peer review publications with articles in various leading oncology journals, namely Lancet, NEJM, Lancet Oncology, Journal of Clinical Oncology, Lancet Gastroenterology and Hepatology, Journal of Hepatology, Gastroenterology and JAMA Oncology. His latest H index is 71 with over 30000 citations in the literature.